Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-loading antigen, mpla and imq, preparation method and application

A vaccine adjuvant and cation technology, which is applied in the field of cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant and preparation, can solve the problems of rapid drug leakage, low biocompatibility, and low drug load.

Active Publication Date: 2021-08-20
INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, liposomes have disadvantages such as low drug loading and rapid drug leakage, and polymer nanoparticles have lower biocompatibility compared with liposomes, in addition to the disadvantages of hydrophilic drug loading and other disadvantages.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-loading antigen, mpla and imq, preparation method and application
  • Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-loading antigen, mpla and imq, preparation method and application
  • Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-loading antigen, mpla and imq, preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0034] The invention provides a preparation method of an antigen-loaded cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant, comprising the steps of:

[0035] S1: Dissolve the amphiphilic triblock copolymer PCL-b-PEG-b-PCL and the cationic phospholipid DOTAP in an organic solvent, then remove the organic solvent by rotary evaporation, and form a uniform film on the bottle wall, blow with nitrogen Dry the residual solvent, then put it in a vacuum drying oven, and dry it in vacuum for 12-24h; wherein, the molecular weight of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL is 10000-24000, preferably 16000, wherein PEG The mass percentage of the hydrophilic segment is greater than 45%, the mass ratio of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL to the cationic phospholipid DOTAP is 20 mg: (0.5-2) mg; the organic solvent is selected from acetonitrile, A mixture of one or more of dichloromethane and chloroform;

[0036] Preferably, it also includes the st...

Embodiment 1

[0041] This embodiment provides a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant loaded with antigen OVA. The preparation method comprises steps:

[0042] S1: Dissolve 20mg of amphiphilic triblock copolymer PCL-b-PEG-b-PCL and 1mg of cationic phospholipid DOTAP in dichloromethane, then remove the organic solvent by rotary evaporation, and form a uniform film on the bottle wall, Dry the residual solvent with nitrogen, then put it in a vacuum drying oven, and dry it in vacuum for 12-24 hours; among them, the molecular weight of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL is 16000, and the PEG hydrophilic chain Segment mass percentage greater than 45%.

[0043] S2: Add 10 mL of double-distilled water to the dried product, hydrate at 65°C for 5 hours, oscillate and mix evenly, and then sonicate for 10 minutes in an ice bath to form a stable emulsion, filter the stable emulsion with a 0.45 μm filter membrane, collect the filtrate, and obtain Cationic pho...

Embodiment 2

[0047] This embodiment provides a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant loaded with TLR7 agonist IMQ and antigen OVA. The preparation method includes the steps:

[0048] S1: 20 mg amphiphilic triblock copolymer PCL-b-PEG-b-PCL, 1 mg cationic phospholipid DOTAP, and 100 μg TLR7 agonist IMQ were dissolved in dichloromethane, and then the organic solvent was removed by rotary evaporation, forming a layer a uniform film, dry the residual solvent with nitrogen, put it in a vacuum drying oven, and dry it in vacuum for 12 hours; wherein, the molecular weight of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL is 16000, of which PEG The mass percentage of the hydrophilic segment is greater than 45%.

[0049] S2: Add 10 mL of double-distilled water to the dried product, hydrate at 65°C for 5 hours, oscillate and mix evenly, and then sonicate for 10 minutes in an ice bath to form a stable emulsion, filter the stable emulsion with a 0.45 μm filter membrane,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-carrying antigen, MPLA and IMQ and its preparation method and application. The vaccine adjuvant carries the TLR7 agonist imiquimod in the hydrophobic core, The phospholipid layer encapsulates the TLR4 agonist monophosphoryl lipid A, absorbs the antigen through the cationic phospholipid DOTAP in the phospholipid layer, protects the antigen through the hybrid nanoparticle and improves the uptake of the antigen by dendritic cells, and significantly enhances the antigen through the TLR agonist Stimulated immune response and significantly improved antigen cross-presentation; as a vaccine adjuvant, the hybrid nanoparticles of the present invention can co-load antigens and different types of TLR agonists at the same time, and can deliver antigens in various immune pathways to promote DC activation and maturation , increase the level of cross-presentation, produce a strong T cell killing effect, induce cytokine secretion, produce long-lasting memory T cell response, and have a good preventive ability against tumors.

Description

technical field [0001] The invention relates to the technical field of vaccine adjuvants, in particular to a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant co-carrying antigens, MPLA and IMQ, as well as its preparation method and application. Background technique [0002] Vaccination is one of the most effective ways to prevent infectious diseases or fight cancer. A successful vaccine should be able to generate long-lasting humoral and cellular immune responses against a specific pathogen. Dendritic cells (DCs) are professional antigen-presenting cells (Antigen-presenting cells, APCs), which play a key role in linking innate and adaptive immune responses. After capturing and presenting antigens, DCs present them to T cells and stimulate CD8 through MHC class I molecules. + Cytotoxic T lymphocyte (CTL) response or activation of CD4 by MHC-II molecules + T cell-mediated humoral immunity. However, protein or peptide antigens in the free state are often c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K9/51A61K47/24A61P35/00
CPCA61K9/5123A61K39/39A61K2039/55511A61P35/00Y02A50/30
Inventor 朱敦皖张琳华务圣洁秦玉张力
Owner INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com